Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00446550
Other study ID # GAU-CL-202
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 11, 2008
Est. completion date August 20, 2009

Study information

Verified date July 2018
Source Amicus Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluated the safety and tolerability of afegostat tartrate in participants with type 1 Gaucher disease who were not receiving enzyme replacement therapy (ERT) or substrate reduction therapy (SRT).


Description:

This was a Phase 2, open-label study in participants with Gaucher disease, a lysosomal storage disorder. Afegostat tartrate (also known as AT2101 or isofagomine tartrate) is designed to act as a pharmacological chaperone by selectively binding to misfolded β-glucocerebrosidase (GCase) and helping it fold correctly, intended to restore GCase activity. The study consisted of a 21-day screening period, a 24-week treatment period, and follow-up visit (Day 183, end-of-study). Participants were randomized in a 1:1 ratio to 1 of 2 treatment regimens for afegostat tartrate (3 days on treatment/4 days off or 7 days on treatment/7 days off).


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date August 20, 2009
Est. primary completion date August 20, 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years to 74 Years
Eligibility Inclusion Criteria:

- Confirmed diagnosis of type 1 Gaucher disease with a known genotype and a documented missense gene mutation in at least 1 of the 2 gene-encoding ß-glucosidase (GBA) alleles

- Clinically stable

- Treatment naïve to ERT and SRT or had not received ERT or SRT in the 12 months before screening

- Willing to not initiate ERT or SRT treatment during study participation

- Male or female participants, 18 to 74 years old, inclusive

- At the screening period (Day -21 to Day -1), participants must have met at least 2 of the following criteria: platelet count of =150,000 per microliter, hemoglobin =12 grams/deciliter (g/dL) for females and =13 g/dL for males, liver volume =1.25 multiples of normal (MN), and spleen volume =2 MN

- All participants of reproductive potential were required to practice an acceptable method of contraception

- Provided written informed consent to participate in the study

Exclusion Criteria:

- A clinically significant disease other than Gaucher disease, severe complications from Gaucher disease, or serious intercurrent illness that precluded participation in the study in the opinion of the investigator

- During the screening period, had any clinically significant findings as deemed by the investigator

- Partial or total splenectomy

- Documentation of moderate or severe pulmonary hypertension, defined as pulmonary arterial pressure >35 millimeters of mercury (mmHg) or significant Gaucher-related lung disease

- History of allergy or sensitivity to the study drug or any excipients, including any prior serious allergic reaction to iminosugars

- Pacemaker or other contraindication for magnetic resonance imaging (MRI) scanning

- Pregnant or breast-feeding

- Current/recent drug or alcohol abuse

- Treatment with any investigational product in the last 90 days before study entry

- Treatment in the previous 90 days with any drug known to have a well-defined potential for toxicity to a major organ

- Presence of symptoms of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs

Study Design


Intervention

Drug:
afegostat tartrate


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Amicus Therapeutics

Countries where clinical trial is conducted

United States,  Israel,  South Africa,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) A TEAE was defined as any adverse event (AE) with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe AE defined as an AE that was incapacitating and required medical intervention. The number of participants who experienced 1 or more severe TEAEs after dosing on Day 1 through the end of follow-up (Day 183) is presented. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module. Day 1 (after dosing) through Day 183
Secondary Change From Baseline To End Of Treatment In ß-glucocerebrosidase (GCase) Levels In White Blood Cells (WBC) GCase is a biomarker used to assess the PD effects of afegostat tartrate. Blood samples were collected to assess GCase levels in WBC. The baseline value was defined as the last non-missing value before the start of study drug. Baseline, Day 169
See also
  Status Clinical Trial Phase
Withdrawn NCT04189601 - Complement Activation in the Lysosomal Storage Disorders
Completed NCT02536911 - A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate Phase 1
Completed NCT04430881 - A National Study in Patients With Unexplained Splenomegaly
Completed NCT02536937 - A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate Phase 1
Completed NCT01411228 - A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease Phase 3
Terminated NCT04094181 - A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies
Completed NCT00391625 - Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT) Phase 1/Phase 2
Completed NCT03625882 - Survey Study for Velaglucerase Alfa (VPRIV) in Japan
Active, not recruiting NCT05526664 - Omics Gaucher Study: Multiomic Approach
Completed NCT02536755 - Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies Phase 3
Recruiting NCT01344096 - Thrombocytopathy in Gaucher Disease Patients N/A
Completed NCT01881633 - A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers Phase 1
Recruiting NCT06116071 - Biomarkers Related to Bone in Pediatric Gaucher Disease
Recruiting NCT01951989 - Intra-monocyte Imiglucerase Kinetics in Gaucher Disease Phase 2
Completed NCT00258778 - Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD) Phase 1
Recruiting NCT04388969 - World Data on Ambroxol for Patients With GD and GBA Related PD
Recruiting NCT05992532 - GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma
Terminated NCT04145037 - Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease Phase 1/Phase 2
Completed NCT00302146 - Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
Active, not recruiting NCT02605603 - SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease